Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Virax Biolabs GroupVRAX +2.64%44 PS Ratio is 134.14 as of Jul. 21, 2026, which is 7% below its 10-year median of 144.17. GuruFocus rates VRAX with a GF Score™ of 44/100 and a GF Value™ of $3.63 (Fairly Valued). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Virax Biolabs Group ranks worse than 87.2% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Virax Biolabs Group's share price is $3.89.
Virax Biolabs Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03. Hence, Virax Biolabs Group's PS Ratio for today is 134.14.
The historical rank and industry rank for Virax Biolabs Group's PS Ratio or its related term are showing as below:
VRAX'
s PS Ratio Range Over the Past 10 Years
Min: 7.87 Med: 144.17 Max: 992.38
Current: 134.13
During the past 7 years, Virax Biolabs Group's highest PS Ratio was 992.38. The lowest was 7.87. And the median was 144.17.
VRAX's PS Ratio is ranked worse than 87.2% of 930
companies
in the Biotechnology industry
Industry Median: 9.35
vs VRAX: 134.13
During the past 7 years, Virax Biolabs Group's highest 3-Year average Revenue per Share Growth Rate was -10.90% per year. The lowest was -54.50% per year. And the median was -47.60% per year.
Back to Basics: PS Ratio
Virax Biolabs Group (NAS:VRAX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Virax Biolabs Group PS Ratio Related Terms
Virax Biolabs Group PS Ratio Historical Data
* Premium members only.
The historical data trend for Virax Biolabs Group's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Virax Biolabs Group's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Virax Biolabs Group PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's PS Ratio distribution charts can be found below:
* The bar in red indicates where Virax Biolabs Group's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Virax Biolabs Group's Share Price of today is $3.89.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $0.03.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Virax Biolabs Group (VRAX) has a PS Ratio of 134.14 as of Jul. 21, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Virax Biolabs Group and its competitors. This is near median its historical median of 144.17. Over the past decade, Virax Biolabs Group's PS Ratio has ranged from 7.87 to 992.38. According to the industry distribution chart, Virax Biolabs Group ranks #811 out of 930 companies in the Biotechnology industry, placing it in the top 87.2%.
Is Virax Biolabs Group's PS Ratio too high?
Virax Biolabs Group's current PS Ratio of 134.14 is near median its 10-year median of 144.17. Over the past 10 years, this metric has ranged from a low of 7.87 to a high of 992.38. The Biotechnology industry median PS Ratio is 9.35. Virax Biolabs Group's value of 134.14 is 1334.7% above this industry median. Based on the distribution chart, Virax Biolabs Group ranks #811 out of 930 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Virax Biolabs Group has a GF Score™ of 44/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Virax Biolabs Group's PS Ratio compare to BBLG and PKTX?
According to the Biotechnology industry distribution chart, Virax Biolabs Group ranks #811 out of 930 companies for PS Ratio. This places Virax Biolabs Group in the lower half of its industry. The industry median PS Ratio is 9.35. Virax Biolabs Group's value of 134.14 is 1334.7% above this benchmark. Historically, Virax Biolabs Group's own PS Ratio has ranged from 7.87 to 992.38 over the past decade. While the company's 10-year median is 144.17 vs. the industry median of 9.35, Virax Biolabs Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.35, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Virax Biolabs Group's current PS Ratio of 134.14 is 1334.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Virax Biolabs Group and its competitors. For the Biotechnology industry, the median PS Ratio is 9.35 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Virax Biolabs Group's current PS Ratio is 134.14, which is near median its own 10-year median of 144.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Virax Biolabs Group stock overvalued right now?
Based on GuruFocus' analysis, Virax Biolabs Group (VRAX) is currently considered Fairly Valued. The stock's GF Value™ is $3.63, compared to a current price of $3.89 — trading 7.2% above its estimated fair value. The current PS Ratio is 134.14, which is near median its 10-year median of 144.17 and 1334.7% above the Biotechnology industry median of 9.35. Virax Biolabs Group's overall GF Score™ is 44/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Virax Biolabs Group (VRAX), the current PS Ratio is 134.14 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Virax Biolabs Group (VRAX) Overvalued in 2026?
Based on GuruFocus' analysis, Virax Biolabs Group stock appears to be overvalued.
The current stock price of $3.89 is trading 7.2% above its estimated GF Value™ of $3.63.
GuruFocus considers Virax Biolabs Group to be Fairly Valued.
Key valuation signals for VRAX:
PS Ratio: 134.14 (near median its 10-year median of 144.17)
GF Value™: $3.63 vs. price of $3.89 (7.2% above fair value)
Industry Position: 1334.7% above the Biotechnology median (#811 of 930)
No single metric tells the full story. See the VRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Virax Biolabs Group Ltd is an inventive biotechnology company focused on the detection of immune responses to and diagnosis of viral diseases. Through its ViraxImmune platform and ImmuneSelect portfolio of research-use-only (RUO) products and services, the Company is building an immune-profiling offering that spans RUO assays, preclinical immunology services and, longer term, T cell-based diagnostics aimed at post-acute infection syndromes (PAIS) such as Long COVID and other chronic conditions linked to immune dysregulation.
44GF Score
Get the complete analysis for VRAX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VRAX has been successfully added to your 
